International controlled clinical trial of thoracic endovascular aneurysm repair with the Zenith TX2 endovascular graft: 1-year results

Jon S. Matsumura, Richard P. Cambria, Michael D. Dake, Randy D. Moore, Lars G. Svensson, Scott Snyder

Research output: Contribution to journalArticle

263 Citations (Scopus)

Abstract

Purpose: This trial evaluated the safety and effectiveness of thoracic endovascular aortic repair (TEVAR) with a contemporary endograft system compared with open surgical repair (open) of descending thoracic aortic aneurysms and large ulcers. Methods: Forty-two international trial sites enrolled 230 subjects with descending thoracic aortic aneurysms or ulcers. The study compared 160 TEVAR subjects treated with the Zenith TX2 Endovascular Graft (William Cook Europe, ApS, Bjaeverskov, Denmark) with 70 open subjects. Subjects were evaluated preprocedure, predischarge, 1, 6, and 12 months, and yearly through 5 years with medical examination, laboratory testing, chest radiographs, and computed tomography scans. Mortality rates, prespecified severe morbidity composite index, major morbidity, clinical utility, aneurysm rupture, and secondary interventions were compared. The TEVAR subjects were evaluated by a core laboratory for device performance, including change in aneurysm size, endoleak, migration, and device integrity. Results: The 30-day survival rate was noninferior (P < .01) for the TEVAR group compared with the open group (98.1% vs 94.3%). The severe morbidity composite index was lower for TEVAR (0.2 ± 0.7 vs 0.7 ± 1.2; P < .01). Cumulative major morbidity scores were significantly lower at 30 days for the TEVAR group compared with the open group (1.3 ± 3.0 vs 2.9 ± 3.6, P < .01). The TEVAR patients had fewer cardiovascular, pulmonary, and vascular adverse events, although neurologic events were not significantly different. Clinical utility for the TEVAR patients was superior to that of the open patients. No ruptures or conversions occurred in the first year. Reintervention rates were similar in both groups. At 12 months, aneurysm growth was identified in 7.1% (8/112), endoleak in 3.9% (4/103), migration (>10 mm) in 2.8% (3/107), and other device issues were rare. None of the patients with migration experienced endoleak, aneurysm growth, or required a secondary intervention. Conclusions: Thoracic endovascular aortic repair with the TX2 is a safer and effective alternative to open surgical repair for the treatment of anatomically suitable descending thoracic aortic aneurysms and ulcers at 1 year of follow-up. Device performance issues are infrequent, but careful planning and regular follow-up with imaging remain a necessity.

Original languageEnglish (US)
Pages (from-to)247-257.e3
JournalJournal of vascular surgery
Volume47
Issue number2
DOIs
StatePublished - Feb 2008
Externally publishedYes

Fingerprint

Controlled Clinical Trials
Aneurysm
Thorax
Thoracic Aortic Aneurysm
Transplants
Ulcer
Endoleak
Equipment and Supplies
Morbidity
Denmark
Rupture
Survival Rate
Tomography
Safety
Mortality
Growth

ASJC Scopus subject areas

  • Surgery
  • Cardiology and Cardiovascular Medicine

Cite this

International controlled clinical trial of thoracic endovascular aneurysm repair with the Zenith TX2 endovascular graft : 1-year results. / Matsumura, Jon S.; Cambria, Richard P.; Dake, Michael D.; Moore, Randy D.; Svensson, Lars G.; Snyder, Scott.

In: Journal of vascular surgery, Vol. 47, No. 2, 02.2008, p. 247-257.e3.

Research output: Contribution to journalArticle

Matsumura, Jon S. ; Cambria, Richard P. ; Dake, Michael D. ; Moore, Randy D. ; Svensson, Lars G. ; Snyder, Scott. / International controlled clinical trial of thoracic endovascular aneurysm repair with the Zenith TX2 endovascular graft : 1-year results. In: Journal of vascular surgery. 2008 ; Vol. 47, No. 2. pp. 247-257.e3.
@article{b226d03d6e7946b9a04c70d3099d5384,
title = "International controlled clinical trial of thoracic endovascular aneurysm repair with the Zenith TX2 endovascular graft: 1-year results",
abstract = "Purpose: This trial evaluated the safety and effectiveness of thoracic endovascular aortic repair (TEVAR) with a contemporary endograft system compared with open surgical repair (open) of descending thoracic aortic aneurysms and large ulcers. Methods: Forty-two international trial sites enrolled 230 subjects with descending thoracic aortic aneurysms or ulcers. The study compared 160 TEVAR subjects treated with the Zenith TX2 Endovascular Graft (William Cook Europe, ApS, Bjaeverskov, Denmark) with 70 open subjects. Subjects were evaluated preprocedure, predischarge, 1, 6, and 12 months, and yearly through 5 years with medical examination, laboratory testing, chest radiographs, and computed tomography scans. Mortality rates, prespecified severe morbidity composite index, major morbidity, clinical utility, aneurysm rupture, and secondary interventions were compared. The TEVAR subjects were evaluated by a core laboratory for device performance, including change in aneurysm size, endoleak, migration, and device integrity. Results: The 30-day survival rate was noninferior (P < .01) for the TEVAR group compared with the open group (98.1{\%} vs 94.3{\%}). The severe morbidity composite index was lower for TEVAR (0.2 ± 0.7 vs 0.7 ± 1.2; P < .01). Cumulative major morbidity scores were significantly lower at 30 days for the TEVAR group compared with the open group (1.3 ± 3.0 vs 2.9 ± 3.6, P < .01). The TEVAR patients had fewer cardiovascular, pulmonary, and vascular adverse events, although neurologic events were not significantly different. Clinical utility for the TEVAR patients was superior to that of the open patients. No ruptures or conversions occurred in the first year. Reintervention rates were similar in both groups. At 12 months, aneurysm growth was identified in 7.1{\%} (8/112), endoleak in 3.9{\%} (4/103), migration (>10 mm) in 2.8{\%} (3/107), and other device issues were rare. None of the patients with migration experienced endoleak, aneurysm growth, or required a secondary intervention. Conclusions: Thoracic endovascular aortic repair with the TX2 is a safer and effective alternative to open surgical repair for the treatment of anatomically suitable descending thoracic aortic aneurysms and ulcers at 1 year of follow-up. Device performance issues are infrequent, but careful planning and regular follow-up with imaging remain a necessity.",
author = "Matsumura, {Jon S.} and Cambria, {Richard P.} and Dake, {Michael D.} and Moore, {Randy D.} and Svensson, {Lars G.} and Scott Snyder",
year = "2008",
month = "2",
doi = "10.1016/j.jvs.2007.10.032",
language = "English (US)",
volume = "47",
pages = "247--257.e3",
journal = "Journal of Vascular Surgery",
issn = "0741-5214",
publisher = "Mosby Inc.",
number = "2",

}

TY - JOUR

T1 - International controlled clinical trial of thoracic endovascular aneurysm repair with the Zenith TX2 endovascular graft

T2 - 1-year results

AU - Matsumura, Jon S.

AU - Cambria, Richard P.

AU - Dake, Michael D.

AU - Moore, Randy D.

AU - Svensson, Lars G.

AU - Snyder, Scott

PY - 2008/2

Y1 - 2008/2

N2 - Purpose: This trial evaluated the safety and effectiveness of thoracic endovascular aortic repair (TEVAR) with a contemporary endograft system compared with open surgical repair (open) of descending thoracic aortic aneurysms and large ulcers. Methods: Forty-two international trial sites enrolled 230 subjects with descending thoracic aortic aneurysms or ulcers. The study compared 160 TEVAR subjects treated with the Zenith TX2 Endovascular Graft (William Cook Europe, ApS, Bjaeverskov, Denmark) with 70 open subjects. Subjects were evaluated preprocedure, predischarge, 1, 6, and 12 months, and yearly through 5 years with medical examination, laboratory testing, chest radiographs, and computed tomography scans. Mortality rates, prespecified severe morbidity composite index, major morbidity, clinical utility, aneurysm rupture, and secondary interventions were compared. The TEVAR subjects were evaluated by a core laboratory for device performance, including change in aneurysm size, endoleak, migration, and device integrity. Results: The 30-day survival rate was noninferior (P < .01) for the TEVAR group compared with the open group (98.1% vs 94.3%). The severe morbidity composite index was lower for TEVAR (0.2 ± 0.7 vs 0.7 ± 1.2; P < .01). Cumulative major morbidity scores were significantly lower at 30 days for the TEVAR group compared with the open group (1.3 ± 3.0 vs 2.9 ± 3.6, P < .01). The TEVAR patients had fewer cardiovascular, pulmonary, and vascular adverse events, although neurologic events were not significantly different. Clinical utility for the TEVAR patients was superior to that of the open patients. No ruptures or conversions occurred in the first year. Reintervention rates were similar in both groups. At 12 months, aneurysm growth was identified in 7.1% (8/112), endoleak in 3.9% (4/103), migration (>10 mm) in 2.8% (3/107), and other device issues were rare. None of the patients with migration experienced endoleak, aneurysm growth, or required a secondary intervention. Conclusions: Thoracic endovascular aortic repair with the TX2 is a safer and effective alternative to open surgical repair for the treatment of anatomically suitable descending thoracic aortic aneurysms and ulcers at 1 year of follow-up. Device performance issues are infrequent, but careful planning and regular follow-up with imaging remain a necessity.

AB - Purpose: This trial evaluated the safety and effectiveness of thoracic endovascular aortic repair (TEVAR) with a contemporary endograft system compared with open surgical repair (open) of descending thoracic aortic aneurysms and large ulcers. Methods: Forty-two international trial sites enrolled 230 subjects with descending thoracic aortic aneurysms or ulcers. The study compared 160 TEVAR subjects treated with the Zenith TX2 Endovascular Graft (William Cook Europe, ApS, Bjaeverskov, Denmark) with 70 open subjects. Subjects were evaluated preprocedure, predischarge, 1, 6, and 12 months, and yearly through 5 years with medical examination, laboratory testing, chest radiographs, and computed tomography scans. Mortality rates, prespecified severe morbidity composite index, major morbidity, clinical utility, aneurysm rupture, and secondary interventions were compared. The TEVAR subjects were evaluated by a core laboratory for device performance, including change in aneurysm size, endoleak, migration, and device integrity. Results: The 30-day survival rate was noninferior (P < .01) for the TEVAR group compared with the open group (98.1% vs 94.3%). The severe morbidity composite index was lower for TEVAR (0.2 ± 0.7 vs 0.7 ± 1.2; P < .01). Cumulative major morbidity scores were significantly lower at 30 days for the TEVAR group compared with the open group (1.3 ± 3.0 vs 2.9 ± 3.6, P < .01). The TEVAR patients had fewer cardiovascular, pulmonary, and vascular adverse events, although neurologic events were not significantly different. Clinical utility for the TEVAR patients was superior to that of the open patients. No ruptures or conversions occurred in the first year. Reintervention rates were similar in both groups. At 12 months, aneurysm growth was identified in 7.1% (8/112), endoleak in 3.9% (4/103), migration (>10 mm) in 2.8% (3/107), and other device issues were rare. None of the patients with migration experienced endoleak, aneurysm growth, or required a secondary intervention. Conclusions: Thoracic endovascular aortic repair with the TX2 is a safer and effective alternative to open surgical repair for the treatment of anatomically suitable descending thoracic aortic aneurysms and ulcers at 1 year of follow-up. Device performance issues are infrequent, but careful planning and regular follow-up with imaging remain a necessity.

UR - http://www.scopus.com/inward/record.url?scp=38649140710&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=38649140710&partnerID=8YFLogxK

U2 - 10.1016/j.jvs.2007.10.032

DO - 10.1016/j.jvs.2007.10.032

M3 - Article

C2 - 18241743

AN - SCOPUS:38649140710

VL - 47

SP - 247-257.e3

JO - Journal of Vascular Surgery

JF - Journal of Vascular Surgery

SN - 0741-5214

IS - 2

ER -